Weight Loss Jabs and the Olympics: A Potential Ban on the Horizon

As the Winter Olympics conclude, the World Anti-Doping Agency (WADA) is actively investigating the potential ban of weight loss jabs – specifically, medications containing semaglutide – for the 2028 Summer Olympics in Los Angeles. This scrutiny stems from concerns about athletes potentially abusing these drugs to gain an unfair competitive advantage and the associated health risks.

The Rise of GLP-1 Medications and Athletic Performance

Semaglutide is the active ingredient in popular GLP-1 receptor agonists, including Ozempic and Wegovy. These medications have gained prominence for their effectiveness in weight management. WADA is now focused on determining whether athletes are utilizing these drugs not for legitimate medical reasons, but to manipulate their weight and enhance performance. Dr. Olivier Rabin, WADA’s senior director of science and medicine, stated the agency aims to “detect patterns of abuse” of these substances in sport, noting a “change in paradigm in the way weight can be controlled” due to their availability. Source

What Criteria Would Lead to a Ban?

For WADA to prohibit the use of these medications, it must establish that athletes are using them to enhance performance, that their health is being jeopardized, or that the spirit of fair play is being violated. Source A decision regarding a potential ban could be made by the finish of 2026 or in 2027, potentially before the Los Angeles Olympic Games. Source

Concerns Beyond Performance Enhancement

The concerns extend beyond simply gaining a competitive edge. Experts highlight potential welfare issues, including the pressure athletes may feel to use these drugs to meet weight standards. Kate Seary, co-founder of Kyniska Advocacy for safe sport, points to “toxic environments where the idea that thin equals speedy, thin equals powerful” persists in some sports. Source

Potential Impact on Athletes

The use of GLP-1 medications can lead to reduced appetite and subsequent energy deficiency. This could negatively impact muscle recovery and nutrient absorption. Source Former medical chiefs for England football teams and Team GB Olympics physicians, Dr. Ian Beasley, suggests athletes might attempt to use these drugs during the off-season to reap benefits during competition, raising questions about detection and measurement. Source

Exemptions and the Challenge of Catching Up

WADA may consider granting exemptions for athletes with legitimate medical needs, such as those with diabetes requiring weight management. However, there is a fear that authorities are currently behind athletes who may already be using these medications. Source

Monitoring and Past Precedents

WADA has been monitoring semaglutide since 2024. Source The agency has a history of moving substances from a monitoring program to a prohibited list once sufficient evidence of abuse is gathered. Tramadol, a powerful painkiller, followed this path, being added to the monitoring list in 2012 and subsequently banned by the UCI in 2019. Source

The ‘Ozempic Olympics’?

The potential for widespread use of these drugs has led some to dub the 2028 Los Angeles Olympics the ‘Ozempic Olympics.’ Source This highlights the growing concern within the sporting world about the ethical and health implications of weight loss medications.